Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 16, 2021 at 09:39 pm
Share
Northwest Biotherapeutics, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 416,000 compared to USD 2,000 a year ago. Operating loss was USD 12.407 million compared to USD 7.536 million a year ago. Net income was USD 4.410 million compared to net loss of USD 58.052 million a year ago. Basic earnings per share from continuing operations was USD 0.01 compared to basic loss per share from continuing operations of USD 0.08 a year ago. For the half year, total revenue was USD 655,000 compared to USD 572,000 a year ago. Operating loss was USD 31.977 million compared to USD 15.369 million a year ago. Net income was USD 287,000 compared to net loss of USD 55.426 million a year ago. Diluted earnings per share from continuing operations was USD 0.03 compared to diluted loss per share from continuing operations of USD 0.08 a year ago.
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Companyâs wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.
NORTHWEST BIOTHERAPEUTICS, INC. 
